44—Intralytix paper E. coli trial

Upuli Dissanayake and colleagues at the University of Florida, along with the US phage company Intralytix, have published a paper showing an E. coli/Salmonella/Listeria-targeting phage cocktail reduces E. coli O157:H7 counts in mice without distorting their gut microbiota.